Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biomarker-directed Neoadjuvant Therapy for Cisplatin-ineligible or Cisplatin-refusing Muscle-invasive Bladder Cancer: Phase I Bladder Cancer Signal Seeking Trial

NCT04972253 is registered in ClinicalTrials.gov with Guru P. Sonpavde as lead sponsor.

NCT NCT04972253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04972253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biomarker-directed Neoadjuvant Therapy for Cisplatin-ineligible or Cisplatin-refusing Muscle-invasive Bladder Cancer: Phase I Bladder Cancer Signal Seeking Trial
Lead sponsor
Guru P. Sonpavde
Phase
Phase 1
Overall status
Withdrawn
Start date
December 23, 2021
Completion date
December 31, 2023
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, bladder transitional cell carcinoma, fibroblast growth factor receptor